Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Chloroquine, hydroxychloroquine and COVID-19

Chloroquine, hydroxychloroquine and COVID-19

Thumbnail Image
Download
Name

nihms-1590215.pdf

Size

80.95 KB

Format

Adobe PDF

Checksum (MD5)

a98d76b3b44a02eee17463301575bf3d

Author(s)
Erickson, T. B.
•
Chai, P. R.
•
Boyer, E. W.
Date Issued
January 2020
Journal
Toxicology Communications
Publisher
Informa UK Limited
Citation
Erickson, T. B. et al. "Chloroquine, hydroxychloroquine and COVID-19." Toxicology Communications 4, 1 (January 2020): 40-42 © 2020 The Author(s)
Version
Author's final manuscript
Abstract
The media have featured the antimalarials chloroquine (CQ) and hydroxychloroquine (HCQ) to treat coronavirus (COVID-19). Political leaders have touted their use and recommended availability to the public. These anti-inflammatory agents have substantial human toxicity with a narrow therapeutic window. CQ and HCQ poisoning cause myocardial depression and profound hypotension due to vasodilation. Bradycardia and ventricular escape rhythms arise from impaired myocardial automaticity and conductivity due to sodium and potassium channel blockade. With cardiotoxicity, ECGs may show widened QRS, atrioventricular heart block and QT interval prolongation. CQ may also cause seizures, often refractory to standard treatment. Of concern is pediatric poisoning, where 1-2 pills of CQ or HCQ can cause serious and potentially fatal toxicity in a toddler. The treatment of CQ/HCQ poisoning includes high-dose intravenous diazepam postulated to have positive ionotropic and antidysrhythmic properties that may antagonize the cardiotoxic effects of CQ. Infusions of epinephrine titrated to treat unstable hypotension, as well as potassium for severe hypokalemia may be required. Current scientific evidence does not support treatment or prophylactic use of these agents for COVID-19 disease. Regulatory and public health authorities recognize that CQ/HCQ may offer little clinical benefit and only add risk requiring further investigation before wider public distribution.
MIT Department
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
http://creativecommons.org/licenses/by-nc-sa/4.0/
Persistent DSpace Link
https://hdl.handle.net/1721.1/125584
DOI of Published Version
https://doi.org/10.1080/24734306.2020.1757967
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.